Pulse Biosciences: Technology Exposed As Worthless By MedTech PHDs

Send us a text Pulse Biosciences [NASDAQ: PLSE] is a medical device company with one product – the CellFX system. PLSE’s history is full of failure and wasted investors’ money trying to sell its technology for skin treatments. With the same team and approach, failure is going to repeat in the company’s pivot to cardiac ablation, or the Pulsed Field Ablation (PFA) market. PLSE is years behind Boston Scientific (Farapulse) and Medtronic (Affera and PulseSelect) in the clinical studies/FDA appr...